Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1675
This examiner grants 80% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18047135 | VIP Antagonists and Uses in Treating Cancer | Non-Final OA | Georgia Tech Research Corporation |
| 17926479 | METHODS FOR TREATING PLASMA PROTEIN IMBALANCES OR DEPLETION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18345975 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 19329431 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | Non-Final OA | Ohio State Innovation Foundation |
| 17922472 | METHODS AND COMPOSITIONS FOR ENHANCING STABILITY AND SOLUBILITY OF SPLIT-INTEINS | Non-Final OA | Ohio State Innovation Foundation |
| 18153872 | TANDEM REPEAT PROTEIN SEQUENCES IN PROTEIN-LIKE POLYMERS AND USES THEREOF | Non-Final OA | Northwestern University |
| 18293692 | COMPOSITIONS AND METHODS FOR TREATING MELANOMA | Non-Final OA | Johns Hopkins University |
| 17482273 | METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | Non-Final OA | SANOFI BIOTECHNOLOGY |
| 18573517 | COMBINATION COMPOSITIONS FOR THE TREATMENT OF PATHOGEN INFECTIONS AND ASSOCIATED COMPLICATIONS | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy